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Abstract
Background: To identify, summarise and synthesise the evidence for using interactive digital interventions to
support patient self-management of asthma, and determine their impact.
Methods: Systematic review with meta-analysis. We searched MEDLINE, EMBASE, CINAHL, PsycINFO, ERIC, Cochrane
Library, DoPHER, TROPHI, Social Science Citation Index and Science Citation Index. The selection criteria requirement
was studies of adults (16 years and over) with asthma, interventions that were interactive digital interventions and
the comparator was usual care. Outcomes were change in clinical outcomes, cost effectiveness and
patient-reported measures of wellbeing or quality of life. Only Randomised Controlled Trials published in
peer-reviewed journals in English were eligible.
Potential studies were screened and study characteristics and outcomes were extracted from eligible papers
independently by two researchers. Where data allowed, meta-analysis was performed using a random effects
model.
Results: Eight papers describing 5 trials with 593 participants were included, but only three studies were eligible for
inclusion for meta-analysis. Of these, two aimed to improve asthma control and the third aimed to reduce the total
dose of oral prednisolone without worsening control. Analyses with data from all three studies showed no
significant differences and extremely high heterogeneity for both Asthma Quality of Life (AQLQ) (Standardised
Mean Difference (SMD) 0.05; 95 % Confidence Interval (CI) 0.32 to −0.22: I2 96.8) and asthma control (SMD 0.21;
95 % CI −0.05 to .42; I2 = 87.4). The removal of the third study reduced heterogeneity and indicated significant
improvement for both AQLQ (SMD 0.45; 95 % CI 0.13 to 0.77: I2 = 0.34) and asthma control (SMD 0.54; 95 % CI 0.22
to 0.86: I2 = 0.11). No evidence of harm was identified.
Conclusion: Digital self-management interventions for adults with asthma show promise, with some evidence of
small beneficial effects on asthma control. Overall, the evidence base remains weak due to the lack of large, robust
trials.
Background
Asthma is a common condition affecting an estimated
300 million people worldwide and is increasing in preva-
lence in many countries [1]. Sub-optimal control of
asthma is common, with patient adherence to regular
preventer medication such as inhaled corticosteroids
(ICS) reported to be as low as 30 % [1], potentially
leading to increased symptoms, increased risk of asthma
attacks and reduced quality of life [2, 3]. Patient educa-
tion and proactive self-management have been shown to
improve clinical outcomes in people with asthma [4, 5].
Guided self-management for asthma is aimed at improv-
ing knowledge of the condition and increasing the ability
of an individual to manage variations in their asthma [6].
This offers the potential for an improved quality of life,
as well as reductions in hospitalisations, emergency
room visits, asthma attacks, unscheduled visits to the
doctor, and days off work in those with asthma [7]. It is
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estimated that only a quarter of asthma patients have a
self-management plan, despite evidence for the benefits
of having one [8]. In most healthcare systems asthma is
predominantly managed in primary care. However, pri-
mary care support for self-management in asthma can
be sub-optimal [9].
One potential method for improving self-management
is through the use of interactive digital interventions
(IDIs), which offer the possibility of enabling patients to
self-manage long-term conditions such as asthma and
hence improve outcomes [10–12]. IDIs are packages that
can combine health information with decision support
to help inform behaviour change in patients, and are
typically delivered through the internet or via smart
phones. They offer the potential to improve the lives of
people with asthma through automating and personalis-
ing routine aspects of education, monitoring and sup-
port, whilst at the same time giving patients convenient
24 h access to detailed, personalised feedback [13, 14].
There is evidence that well-designed IDIs can change
patient health-related behaviour, improve patient know-
ledge and increase confidence for self-management of
health problems [10, 11, 15].
There is little work assessing the impact of IDIs on
asthma outcomes. Previous reviews of internet-based in-
terventions have generally focused on telemedicine,
where support may not necessarily be interactive or tai-
lored to the user, finding that these interventions im-
proved medication adherence [16] but did not improve
asthma symptom scores [17]. Studies that have focused
solely on self-management IDIs in those with asthma
have included both children and adults and not re-
stricted comparisons to usual care [18, 19]. Results of
these reviews suggested that IDIs improved markers of
self-care and knowledge, but evidence of improvement
in clinical outcomes such as lung function were less
clear [18, 19]. The successful implementation of IDIs
into primary care will depend, at least in part, on their
benefits and cost-effectiveness being clearly demon-
strated to primary care clinicians [20, 21]. Therefore we
undertook this systematic review to identify, summarise
and synthesise the evidence for using IDIs to support pa-
tient self-management of asthma, and determine their
impact on clinical outcomes, control and knowledge of
asthma, quality of life, medication adherence, health ser-
vice utilisation and cost-effectiveness.
Methods
Design
Systematic review and meta-analysis.
A registered protocol (PROSPERO 2014: CRD420140134
55) guided the conduct of this review [22], which is re-
ported in adherence to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) State-
ment [23].
Eligibility criteria
Inclusion criteria were based on the PICOS (Population,
Intervention, Comparator, Outcomes, Study type) acro-
nym (http://library.med.nyu.edu/library/instruction/hand-
outs/pdf/picohandout.pdf). The population was adults
with asthma. We defined adults as people aged 16 years
and over. Where studies included participants below
16 years of age, the study was only included if we were
able to extract the data on those aged 16 or over. The
intervention was an interactive digital intervention (as de-
fined below); the comparator was usual care; outcomes
were objectively measured change in clinical outcomes
and / or patient-reported outcomes of wellbeing or quality
of life; and the study type was Randomised Controlled Tri-
als (RCTs) as they present the strongest level of evidence.
Finally, we only considered studies published in peer-
reviewed journals in English as evidence suggests that lim-
iting studies in this way does not introduce significant bias
[24] but does save considerable resource.
For the purpose of this review the term IDIs will in-
clude any intervention accessed through a computer
(work or home), or smartphone or other hand held de-
vice and include web based programmes, desktop com-
puter programmes or apps that provide self-
management information and can be used on or offline.
The intervention must function without the need for
directive input from a health professional. They must
also be ‘interactive’, which we define as requiring contri-
butions from programme users (e.g. entering personal
data, making choices) which alter pathways within pro-
grammes to produce tailored material and feedback that
is personally relevant to users.
Information sources and search strategy
Searches were undertaken by the York Health Eco-
nomic Consortium, a professional systematic review
company (http://www.yhec.co.uk/). The strategies
were informed by the intervention search terms used
in a previous systematic review conducted by the
team on digital asthma self-management interventions
[18]. The search strategy combined 3 concepts and a
study type filter for RCTs:
1. Asthma
2. Digital interventions
3. Self-management/behaviour change/patient
experience
4. RCTs
The following databases were searched: MEDLINE,
EMBASE, CINAHL, PsycINFO, ERIC, Cochrane Library
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(including CDSR, DARE, Central, NHS EED and HTA
databases), DoPHER and TROPHI (both produced by
the EPPI Centre), Social Science Citation Index and
Science Citation Index. These databases were
searched using a combination of subject headings
where available (such as MeSH) and words in the title
and abstracts. The search strategy for MEDLINE is
available in Additional file 1 and was adapted for use
in the other databases.
The search was complemented by contacting experts
in the topic under review and by carrying out citation
searches for included studies [25].
Study selection
Following de-duplication, all abstracts identified from
the search were downloaded into the Distiller software
programme (https://distillercer.com/products/distillersr-
systematic-review-software/). Abstracts and full papers
were screened by two reviewers working independently
against the inclusion criteria. Inter-reviewer disagree-
ments were resolved by discussing whether the paper
met the inclusion / exclusion criteria. If consensus be-
tween the reviewers was not possible, the decision was
referred to the steering group.
Data extraction
We used online data collection forms using Distiller SR
software. Two independent researchers extracted data
on study details (country of origin, inclusion/exclusion
criteria, number of participants), participant details
(mean age, % male, ethnicity, socio-economic status,
smoking status and comorbidities), intervention details
(description, theoretical basis, setting, duration, intensity
and format) and outcomes. Outcomes were classified
into clinical outcomes (asthma control, symptoms (e.g.
diary card scores), lung function); asthma-related quality
of life; behavioural outcomes (e.g. medication adher-
ence): cognitive outcomes (knowledge of condition, sat-
isfaction with care); affective outcomes (change in
depression or anxiety); and economic outcomes (use of
health service resources, costs of intervention).
Assessment of methodological quality
Risk of bias was assessed in each of the included studies
by the two researchers working independently, using the
Cochrane collaboration tool for assessing bias for guid-
ance [26]. Methods of allocation concealment, random-
isation procedure, dropout rate and whether there was
evidence of selective outcome reporting were assessed.
Analysis of interventions
Meta-analysis was based on guidelines from the
Cochrane Handbook for Systematic Reviews of Interven-
tions [27]. Potential publication bias was assessed by
using a funnel plot and Egger’s test [28]. Where the
quantity and quality of data permitted, we undertook
meta-analysis, using standardised mean differences and a
random effects model (DerSimonian–Laird method)
[27]. Where several papers reported the same study, we
took the one with the longest duration of follow-up.
Where standard deviation of the change was not re-
ported we estimated the standard deviation using confi-
dence intervals or p-values [27]. Heterogeneity statistics
were assessed by the Q statistic and I2 statistics [29]. For
the Q statistic, p < 0.10 was considered to indicate statis-
tically significant heterogeneity. The I2 statistic indicates
the percentage of the observed between-study variability
due to differences in study populations, interventions or
methods, rather than chance, with the following sug-
gested ranges: no heterogeneity, I2 = 0–25 %; moderate
heterogeneity, I2 = 25–50 %; large heterogeneity, I2 = 50–
75 %; and extreme heterogeneity, I2 = 75–100 % [27].
Results
Our search identified 1875 unique citations of which 46
required full paper review. Eight papers reporting five
studies with 593 participants met our criteria and were
included (see Fig. 1).
Description of Included studies
Of the eight included papers, four papers reported from
the SMASHING study [30–33] For this study, one paper
was selected as the primary data source for the meta-
analysis, based on length of follow-up) [30]. Where ne-
cessary, data from this publication were supplemented
3311 studies identified – following
de-duplication 1875 records
remained
Abstract screening
46 included
for full paper screening
8 papers from 5 interventions
included
37 excluded
Reasons (paper can
be excluded for
more than one
reason)
Not about adults 1
(2.7%)
Not in English 3
(8.1%)
Not about asthma 1
(2.7%)
Not a digital
intervention 15
(40.5%)
Not about self -
management 7
(18.9%)
Not RCT 5 (13.5%)
Does not include
quantitative analysis
3 (8.1%)
Comparison group
not usual care
5 (13.5%)
Fig. 1 PRISMA Flowchart depicting the study selection procedure
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with data from accompanying papers (e.g. for a more de-
tailed description of the intervention).
The five included studies had a total of 593 partici-
pants (range 50 – 200) (Table 1). In addition to the
SMASHING study one further intervention was under-
taken in the Netherlands [34]. The remaining studies
were conducted in the USA [35], Taiwan [36] and
Denmark [37]. The studies varied considerably in the na-
ture and delivery of the intervention, the study popula-
tion, and the outcome measures used.
Description of Interventions
A summary of the key components of the interventions
is given in Table 2.
Aim of intervention
Three of the interventions, led by Rasmussen and van
der Meer (the SMASHING study) directly tested the im-
pact of a digital intervention on asthma outcomes as a
main objective [31–33, 36, 37]. Two studies focused on
medication: Hashimoto et al. [34] assessed whether
home monitoring of symptoms, lung function and frac-
tion of exhaled nitric oxide facilitates tapering of oral
corticosteroids and leads to reduction of corticosteroid
consumption without worsening asthma control or
asthma-related quality of life; Bender et al. [35] tested
whether an interactive voice response system could im-
prove adherence to controller medications.
Format and delivery
In the SMASHING study, participants accessed the
intervention through a specially designed website, which
allowed patients to report daily lung function (FEV1)
values through the website or by text message [30–33].
In the Hashimoto et al. study, patients registered their
daily FEV1 values, dose of oral corticosteroids and ex-
haled nitric oxide (FENO) to an asthma monitoring ser-
vice using an internet application or text messages [34].
Bender et al. used an interactive voice response system
(IVR) through which participants received calls, and
gave tailored responses based on information given by
the participant [35]. Liu et al. used interactive self-care
software installed on patients’ mobile telephones to rec-
ord daily sleep quality, coughing severity, difficulties
with breathing, activities affected by asthma, use of re-
lievers, peak expiratory flow rate (PEFR) and PEFR vari-
ability [36]. Participants were loaned a mobile telephone
if they did not have one or it was not compatible with
the software. Rasmussen et al. used an internet-based
asthma management tool; if the patient did not have ac-
cess to a computer, a push-button telephone was used
[37].
Education
All the studies provided additional education via the
intervention. This was poorly described in some and
very variable in content. Two studies described the edu-
cation provided by the intervention: the SMASHING
study [30–33] featured two group-based education ses-
sions, which lasted 45 to 60 min, including exploration
of a patient’s interests and previous knowledge (negotiat-
ing an agenda and patient-centred education), personal-
ized feedback, and support for self-management (self-
efficacy and implementing a plan for change); the
Bender et al. study included information about a pre-
existing free telephone service staffed by nurses capable
of answering questions about asthma, and the Colorado
Quit Line, offering free telephone based tobacco cessa-
tion information [35].
Additional health professional help available
Three of the studies specified that additional health pro-
fessional help could be accessed through the interven-
tion if participants required it. In the SMASHING study,
intervention participants could communicate with a spe-
cialised asthma nurse if required [30–33]. In the Hashi-
moto et al. intervention a study nurse could monitor
data entered at the web page and facilitate communica-
tion between patients and pulmonologists, if deemed ne-
cessary [34]. For the Rasmussen et al. intervention
participants had access to a physician for treatment ad-
vice [37].
Setting
Two studies were conducted in general practice, 2 in
outpatient clinics and one in a community clinic (see
Table 2).
Duration and intensity
The SMASHING study was the longest intervention at
twelve months [30–33]. The shortest was the Bender et
al. study, which lasted 10 weeks [35]. The three
remaining studies were all 6 months in duration. All
studies required daily input by intervention participants
with the exception of the Bender et al. study, in which
participants received 2 or 3 telephone calls in the 10-
week time period.
Theoretical basis for intervention included in paper
Two of the studies outlined a theoretical basis for their
intervention. The SMASHING study used the Chronic
Care model. This is aimed at improving health care out-
comes for patients with a chronic disease by means of a
proactive patient-professional partnership that addresses
both organisational factors (such as decision support
systems) and resources (such as self-management sup-
port) [30–33]. Bender et al. used the benefit risk model
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Table 1 Characteristics of included papers
Author (Year) Definition of Asthma Population
Numbers
(I = Intervention,
C = Control)
Mean Ethnicity
(I = Intervention,
C = Control
N (%) Outcomes assessed Main results
Age (years) Males
Location (I = Intervention,
C = Control
(I = Intervention,
C = Control
van Gaalen
[30] (2013)
Netherlands
physician-diagnosed
prescription of inhaled
corticosteroids
≥3 months in the
previous year
I =47,
C = 60
I = 37.0
C = 36.
N/A I = 12 (26),
C = 19 (32)
AQLQ, ACQ, Symptom-free
days, FEV, daily inhaled
corticosteroids(DCID
At 30 months after baseline, a
sustained and significant
difference in terms of asthma-
related quality of life of 0.29
(95 % CI 0.01-0.57) and asthma
control of −0.33 (95 % CI
−0.61 to −0.05) was found in
favor of the Intervention
group. No sig differences were
found for FEV2 or daily inhaled
corticosteroids
Van der Meer
[31] (2009)
Netherlands
Physician-diagnosed
prescription of inhaled
corticosteroids
≥3 months in the
previous year
I = 99
C = 101
I = 37.0
C = 36.0
N/A I = 29(29)
C = 32 (32)
Asthma knowledge, Inhaler
technique, Self-reported
medication adherence,
Physician visits, Telephone
contacts, medication changes,
AQLQ, ACQ, Symptom-free
days, FEV, DCID
Asthma-related quality of life
showed a greater increase in
the intervention
group(adjusted between-
group difference, 0.38 [95 %
CI, 0.20 to 0.56]). . Asthma
control improved more in the
I group than in the UC group
(adjusted difference, _0.47 [CI,
_0.64 to _0.30]).
Van der Meer
[32] (2010)
Netherlands
physician-diagnosed
prescription of inhaled
corticosteroids
≥3 months in the
previous year
I = 99
C = 101
(subgroups )
well controlled
asthma
(I = 37, C = 38),
partly controlled
asthma
(I = 38, C = 33),
Uncontrolled
asthma
(I = 26, C = 28)
well controlled
asthma
(I = 35.8, C = 36.7),
partly controlled
asthma
(I = 35.5, C = 36.3),
Uncontrolled
asthma
(I = 36.9,
C = 36.0)
N/a well controlled
asthma
(I = 11(29.7 %),
C = 12(31.6 %)),
partly controlled
asthma
(I = 8 (21.1 %)
C = 10 (30.3)),
Uncontrolled
asthma I =
13(50.0 %)
C = 7 (25.0)
Self-reported medication
adherence, , medication
changes,ACQ, daily inhaled
corticosteroids(DCID)
Improvements in ACQ score
after 12 months were −0.14
(p = 0.23), −0.52 (p < 0.001) and
−0.82 (p < 0.001) in the
intervention group compared
to usual care for patients with
well, partly and uncontrolled
asthma at baseline,
respectively. Daily inhaled
corticosteroid dose
significantly increased in the
Internet group compared to
usual care in the first
3 months in patients with
uncontrolled asthma (+278 μg,
p = 0.001
Van der Meer
[33] (2011)
Netherlands
physician-diagnosed
prescription of inhaled
corticosteroids
≥3 months in the
previous year
I = 99
C = 101
I = 37.0
C = 36.0
N/A I = 29(29)
C = 32 (32)
quality adjusted life years
(QALYs), costs for health care
use and absenteeism
QALYs did not statistically
significantly differ between the
Intervention group and usual
care. Costs of the Internet-
based intervention were $254
(95 % CI, $243 to $265) during
the period of 1 year. From a
societal perspective, the cost
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Table 1 Characteristics of included papers (Continued)
difference was $641 (95 % CI,
$21957 to $3240). From a
health care perspective, the
cost difference was $37 (95 %
CI, $2874 to $950).
Hashimoto
[34] (2011)
Netherlands
diagnosis of severe
refractory asthma
according to the major
and minor criteria
recommended by the
American Thoracic
Society
I = 51
C = 38
I = 48.5
C = 52.4
n/a I = 23 (45)
C = 18 (47)
AQLQ, ACC, Slope FEV1,
Exacerbations, Days of
hospitalisation per patient, ICS,
Sparing of oral corticosteroids,
prednisone dose
Median cumulative sparing of
prednisone was 205 (25-75th
percentile 221 to 777) mg in
the internet strategy group
compared with 0 (497 to
282) mg in the conventional
treatment group (p = 0.02).
Bender
[35] (2012)
USA
Physician diagnosed
asthma for which they
were prescribed
daily inhaled
corticosteroid treatment
I = 25, C = 25 I = 39.6
C = 43.5
I = 56 % white, 24 %
Hispanic, 20 %
African American,
0 % Asian.
C = 60 % white, 12 %
Hispanic, 20 %
African American,
0 % Asian.
I = 10 (40 %)
C = 8(32 %)
Medication Adherence, Belief
in Medications Questionnaire,
AQLQ, ACT
No differences emerged for
the AQLQ or ACT. Adherence
was 32 % higher in
intervention group and
increased score in belief in
medication was found for
intervention group
Liu
[36] (2011)
Taiwan
moderate-to-severe
persistent asthma based
on criteria for asthma as
defined by the American
Thoracic Society on the
basis of clinical
symptoms and physical
examination.
I = 43
C = 46
I = 50.4
C = 54
n/a I = 22(51 %),
C = 22(47.8 %)
PEFR L-min-, FEV1 % pred, SF-
121 physical component score,
SF-121 mental component
scoreCS, inhaled corticoste-
roids dosage, Systemic steroid
dosage, Antileukotriene,
exacerbations, unscheduled
visits to hospital
In the intervention, mean SEM
peak expiratory flow rate
significantly increased at 4)
and 6 months (compared to
the control group. The
intervention group also had
better quality of life after
3 months, as determined
using the Short Form-121
physical component score,
and fewer episodes of
exacerbation and unscheduled
visits than the control group.
Rasumussen
[37] (2013)
Denmark
diagnosed on the basis
of a combination of
respiratory symptoms
and at least one
objective measurement
of asthma (i.e., airway
hyper responsiveness to
inhaled methacholine of
<4 mmol, peak
expiratory flow [PEF]
variability of >20 %,
and/or a minimum of
15 % [300 mL] increase
in FEV1 after
bronchodilation)
I = 80
C = 85
I = 28
C = 30
N/A I = 27(33.9 %)
C = 30 (35.3.7 %)
Symptoms, AQLQ, FEV1
_300 mL, airway hyper
responsiveness.
Improvement was found for
the intervention group versus
control for asthma symptoms
Internet vs GP: odds ratio of
3.26; P < .001, AQLQ (odds
ratio of 2.10, P = .04) lung
function (odds ratio of 4.86,
P < .001), airway hyper
responsiveness. (odds ratio of
3.06, P = .02)
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which posits that the probability of engaging in health-
promoting behaviours depends on the person’s percep-
tion of risk and benefit related to the behaviour and its
health consequence [35].
Description of the study population
Characteristics of participants in the included studies are
in Table 1, and showed considerable variation. Authors
differed on how they defined asthma. The SMASHING
study used physician-diagnosed asthma coded according
to the International Classification of Primary Care in the
electronic medical record and prescription of inhaled
corticosteroids for at least 3 months in the previous year
[30–33]. The sample in the Hashimoto et al. study had
severe refractory asthma as defined by the American
Thoracic Society [34]. Bender et al. used physician diag-
nosed asthma for which patients were prescribed daily
inhaled corticosteroid treatment [35]. Liu et al. based
their definition on clinical symptoms and physical exam-
ination, using the criteria for moderate to severe asthma
as defined by the American Thoracic Society [36]. The
Rasmussen et al. definition was based on a combination
of respiratory symptoms and at least one objective meas-
urement of asthma [37].
The percentage of male participants ranged from
28.9 % [30] to 49.4 % [36] and mean age ranged from 28
[37] years to 54.0 [36]. Only Bender et al. recorded the
ethnicity of the participants [35]. Only van der Meer re-
ported on socio-economic differences by recording the
education status of participants [31].
Quality appraisal
Details of the quality appraisal of the included studies
can be found in Table 3. All the included studies were
randomised controlled trials but two interventions were
deemed to have an inadequate randomisation procedure
[30, 31] and one was unclear on how the randomisation
procedure took place [37]. Allocation concealment was
only clear in two studies [35, 37]. One study had a drop-
out rate greater than 20 % [36]. Three of the studies did
not control for any potential confounders in their ana-
lysis [35–37]. The majority of the studies were short in
duration and relatively small in size, meaning that they
were likely to be under-powered.
Outcomes
Quality of life questionnaires
Four of the five studies reported on asthma specific
quality of life indicators using the Juniper AQLQ
questionnaire [30–35, 37] while Liu et al [36] used
the Short Form (SF)-12 questionnaire to measure
physical and mental health as general indicators of
quality of life. Liu found that patients in the interven-
tion group had a statistically significant improvement
in physical health, with significantly higher physical
health status than the control group at three months,
and at the end of the intervention at six months. The
mental health status (SF-12) of patients in the mobile
phone intervention group did not significantly change
throughout the study period. Patients in the control
group showed a significant reduction in mental health
status by the end of the study. Van der Meer et al.
Table 2 Description of Interventions
Author (Year) Mode of delivery Health Education
Included
Setting Frequency of use Theoretical basis
included in paper
Duration
Van Gaalen [30] Website/mobile
phone
Yes General practice Daily Yes
(Chronic care model)
12 months
Van der Meer [31–33]
Hashimoto [34] Website Yes Hospital Outpatients Daily No 6 months
Bender [35] Phone/Interactive
Voice response
Yes Community/clinic 2 or 3 calls in
time period
Yes (Benefit risk model) 10 weeks
Liu [36] Mobile Phone Yes Outpatient clinic Daily No 6 months
Rasmusen [37] Website Yes General practice Daily No 6 months
Table 3 Quality appraisal for included studies
Author (Year) Appropriate Randomisation
Technique
Allocation
concealment
Dropout rate
<20 %
Potential confounders
properly accounted for
Were eligibility
clear
Van Gaalen [30] No No Yes Yes Yes
Van der Meer [31–33]
Hashimoto [34] No No Yes Yes Yes
Bender [35] Yes Yes Yes No Yes
Liu [36] Not clear Not clear No No Yes
Rasmusen [37] Yes Yes Yes No Yes
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reported a significant improvement in the interven-
tion group compared to usual care by the end of the
intervention (difference 0.38 95%CI 0.20 to 0.56) [31].
Rasmussen et al. used odds ratios in measuring
change in AQLQ and therefore was excluded from
the meta-analysis. They found that those in the inter-
vention group were twice as likely to show an im-
provement in AQLQ compared to the usual care
group (OR 2.10, 95 % CI 1.02-4.31) [37].
This left three papers to be included in the meta-
analysis with 123 intervention and 123 control patients
(Fig. 2) [30, 34, 35]. This initial meta-analysis demon-
strated no significant change in Asthma Quality of Life
(AQLQ) (SMD 0.05; 95 % CI 0.32 to −0.22) with a high
level of heterogeneity (I2 = 96.8; Q = p < 0.001). The Ha-
shimoto et al. study37 was removed as its’ aim was to re-
duce the total dose of oral prednisolone without
worsening control compared to the other two studies
which was to improve asthma control. Figure 3 shows
this reduced heterogeneity and the meta-analysis then
showed significant improvement in AQLQ for interven-
tion groups (SMD 0.45; 95 % CI 0.13 to 0.77: I2 = 0; Q =
p = 0.34).
Asthma control questionnaires
Three of the interventions and five papers reported on
measures of asthma control using a range of asthma
control questionnaires (ACQ) [30–32, 34, 35]. Van der
Meer et al. found for patients with well controlled
asthma at baseline ACQ scores were not significantly
different between the usual care and intervention group
during follow-up. In patients with partly controlled
asthma at baseline ACQ scores in the intervention group
improved with −0.44 (95 % CI, −0.67 to −0.22) and
−0.51 (− 0.73 to −0.29) after 3 and 12 months, respect-
ively, compared to usual care. In patients with uncon-
trolled asthma at baseline ACQ scores in the
intervention group improved with −0.57 (95 % CI, −0.84
to −0.31) and −0.82 (−1.10 to −0.55) after 3 and
12 months, respectively, compared to usual care and
overall −0.47 (95 % CI, −0.64 to −0.30) after 12 months
[31, 32]. This left three papers [30, 34, 35] included in a
meta-analysis with 123 intervention and 123 control pa-
tients (Fig. 4). Overall they showed no significant differ-
ence in asthma control (SMD 0.21; 95 % CI −0.05 to 0
.46) with relatively high levels of heterogeneity recorded
(I2 = 87.4; Q = p < 0.001). Again, after the removal of the
.       (-19.81, 19.73)with estimated predictive interval
I-V Overall  (I-squared = 96.8%, p = 0.000)
Study
D+L Overall
Hashimoto
van Gaalen
Bender
ID
0.05 (-0.22, 0.32)
-0.04 (-1.58, 1.50)
-1.44 (-1.91, -0.97)
1.08 (0.68, 1.49)
0.23 (-0.33, 0.79)
SMD (95% CI)
100.00
Weight
32.84
43.60
%
23.57
(I-V)
Usual Care improvesasthma AQLQ Intervention improves AQLQ
0-1.91 1.91
Fig. 2 Forest plot of the effect of digital intervention on improvement in Asthma quality of life questionnaires (AQLQ)
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Hashimoto et al. study [34], a small but significant im-
provement in ACQ was found for intervention patients
with moderate heterogeneity recorded as shown by Fig. 5
(SMD 0.54; 95 % CI 0.22 to 0.86: I2 = 0.59.3;Q = p =
0.11).
Forced expiratory volume in 1 second (FEV1)
Four studies examined changes in FEV1 [31, 34, 36, 37],
although meta-analysis was not possible as some re-
ported % predicted FEV1 [36] and others absolute FEV1
[31, 36, 37]. Van der Meer et al. found that mean pre-
bronchodilator FEV1 changed by 0.24 L versus −0.01 L
(adjusted difference, 0.25 [CI, 0.03 to 0.47 L] for the
intervention and usual care groups, respectively [31].
Hashimoto et al. found no significant difference in
changes in FEV1 between intervention and usual care
groups [34]. Liu et al. used FEV1 % predicted and found
that compared to the control group it significantly in-
creased at 6 months (from 43.0 to 65.2 %predicted in
the intervention group versus 46 to 56.5 %predicted in
the control group p < 0.05) [36]. Rasmussen et al. found
that those in the intervention group were significantly
more likely to show an improvement in FEV1 of 300 mL
or more at follow-up with 32 % in the intervention
group improving compared to 9 % in the usual care
group (OR 4.86; 1.97–11.94) [37].
Other clinical outcomes
Liu et al. found that peak expiratory flow rate (PEFR) in-
creased significantly from 4 months onwards in the
intervention group, with the biggest difference recorded
at the end of the six–month study (intervention group
382.7 L-min versus control group 343.5 L-min; p <
0.005) [36]. Rasmussen et al. found that 21 % of those in
the intervention group compared to 8 % in the control
group showed an improvement in airway responsiveness
to inhaled methacholine by one or more dosage steps
(OR 3.06 95 % CI 1.13–3.81) [37].
Asthma symptoms
Van der Meer et al. found the number of asthma symp-
tom free days showed a significant improvement in the
intervention group from baseline to follow up (44.9 % to
63.1 %) compared to controls (44.5 % to 51.8 %) [31]. At
follow up Rasmussen et al. found that 64 % of the inter-
vention group showed an improvement in symptoms (as
defined as improvement of one or more severity steps)
compared to 35 % in the control group (OR 3.26 95 %
.       (  -  ,  -  )Inestimable predictive distribution with <3 studies
I-V Overall  (I-squared = 0.0%, p = 0.345)
D+L Overall
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Fig. 3 Revised forest plot of the effect of digital intervention on improvement in Asthma quality of life questionnaires (AQLQ)
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CI 1.71–6.91) [37]. The severity of symptoms was graded
as follows: very mild, respiratory symptoms less than
once a week and nocturnal symptoms not more than
twice a month; mild, respiratory symptoms 2 to 6 times
a week and nocturnal symptoms more than twice a
month but not weekly; moderate, respiratory symptoms
daily and nocturnal symptoms more than once a week;
and severe, respiratory symptoms constantly and noctur-
nal symptoms more than 4 times a week [37].
Educational outcomes
Van der Meer et al. used the 12-item Consumer Asthma
Knowledge Questionnaire [31] and found no significant
differences in improvements in asthma knowledge or in-
haler technique between intervention and controls [31]
using the standardised checklist of the Dutch Asthma
Foundation [38].
Corticosteroids (inhaled or oral)
Four studies examined changes in use of corticosteroids,
however due to using different measurements; a meta-
analysis was not possible. Van Galen et al. found no sig-
nificant difference in daily inhaled corticosteroid dose
[30] while Van der Meer et al. also found that daily in-
haled corticosteroid dose did not differ statistically sig-
nificantly after 12 months [31]. Hashimoto et al.
measured the cumulative reduction of oral corticosteroid
exposure (actual cumulative dose minus the expected
cumulative dose) [34]. The median cumulative sparing
of prednisone equivalent after 6 months was significantly
higher in the intervention group at 205 mg (25-75th per-
centile −221 to 777 mg) compared with 0 mg (−497 to
282 mg) in the control group (p = 0.02) [34]. In the Liu
et al. study those in the intervention group significantly
increased their mean daily dose of both systemic and in-
haled corticosteroids from baseline, and no significant
change was found in the control group. However,
there was no significant difference between interven-
tion and control groups at the end of the study
period [36]. Rasmussen et al. found that significantly
more patients in the intervention group used inhaled
corticosteroids compared to the control group, in-
creasing from 21 % at baseline to 91 % at follow up
in the intervention group, compared with an increase
from 17 % at baseline to 29 % at follow up in the
control group [37].
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Other medications
Liu et al. reported that the percentage of patients treated
with antileukotrienes was significantly higher in the
intervention group at two months (intervention 60.5 %
versus control 34.8 %; p = 0.015) but this difference had
disappeared by the end of the study (intervention 39.5 %
versus 34.8 %; p > 0.05) [36].
Medication adherence
Van der Meer et al. found no significant difference be-
tween intervention and control groups in self-reported
medication adherence [31]. Bender et al. found that
mean inhaled corticosteroids adherence (determined by
dividing the number of inhaler puffs taken each day by
the number of puffs prescribed to be taken each day,
and then averaged over the 10-week interval) was higher
in the intervention than in the control group by a mar-
gin of 64.5 % to 49.1 % (p =0.03) [35]. The two groups
also differed on the Belief in Medication Questionnaire,
with the intervention group demonstrating a greater up-
ward shift in positive medication beliefs, possibly
explaining the improved adherence observed (p = 0.007)
[35]. Rasmussen et al. found that compliance (defined as
use of medication always or almost always) was
significantly higher in the intervention group, with 87 %
compliance compared with 54 % in the control group (p
< 0.001) [37]. Rasmussen et al. also found that all inter-
vention patients were on some form of asthma medica-
tion at follow up, compared to 74 % in the control
group (p < 0.001) [37].
Exacerbations and health care utilisation
Van der Meer et al. found no significant differences in
physician visits or telephone contacts with health pro-
vider between intervention and controls [31, 36]. Hashi-
moto et al. found no significant differences in
exacerbations per patient or per year or days of hospital-
isation between intervention and control groups [34].
Liu et al. reported fewer unscheduled visits and a lower
number of patients visiting the emergency department
in the intervention group versus the control group [36].
Cost effectiveness
Van der Meer et al. reported that quality adjusted life
years, as measured by the EuroQol-5D, did not signifi-
cantly differ between the intervention and control group
[32]. Costs of the Internet-based intervention were $254
per patient (95 % CI, $243 to $265) during the period of
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D+L Overall
Study
ID
Van Gaalen
Bender
0.54 (0.22, 0.86)
0.49 (-0.04, 1.02)
SMD (95% CI)
0.72 (0.33, 1.12)
0.18 (-0.38, 0.73)
100.00
%
Weight
(I-V)
66.52
33.48
Usual Care improves asthma control Intervention improves asthma control 
0-1.12 1.12
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1 year. Measuring from a societal perspective, the cost
difference was $641 (95 % CI, $21957 to $3240), and
from a health care perspective, the cost difference was
$37 (95 % CI, $2874 to $950). At a willingness-to-pay of
$50000 per QALY, the probability that Internet-based
self-management was cost-effective compared to usual
care was 62 % and 82 % from a societal and health care
perspective, respectively [32].
Discussion
This systematic review and meta-analysis of IDIs for
self-management in adult asthma found only eight pa-
pers reporting five eligible studies. The studies were gen-
erally of moderate quality, small in size and short in
duration, and used heterogeneous interventions. The
quality and small number of included studies limits the
conclusions from this review of IDIs. “The results were
complicated further by the Hashimoto et al. study,
whose aim was to investigate whether their intervention
could facilitate tapering of oral corticosteroids in oral
steroid dependent patients without worsening asthma
control or asthma-related quality of life [34]. Inclusion
of the Hashimoto study in the meta-analysis led to sig-
nificant heterogeneity for both asthma control and
asthma quality of life. Once the Hashimoto et al. study
was removed, a small but significant improvement was
found for both asthma control and AQLQ, albeit based
on only two studies. Given the aim of the Hashimoto
study it many be considered that the meta-analyses of
the two remaining trials offers a more valid result. How-
ever, although the results of the revised meta-analysis
were statistically significant it remained lower than 0.5
which is considered to be the minimal level for the dif-
ference to be clinically significant [38, 39] suggesting the
impact of the interventions may be clinically limited.
The effect of IDIs on other clinical outcomes is uncer-
tain, due to the low number of studies and use of differ-
ent metrics, which meant that meta-analysis was not
possible. However, none of the studies reported signifi-
cantly worse outcomes in the intervention groups for
any indicator, with most reporting improvements in a
range of other clinical outcomes.
This study builds on previous work [18] in looking at
the impact of IDIs by using a more refined search strat-
egy which focuses on adults only and using only inter-
ventions where the comparator group is usual care. This
allows for the impact on adults with asthma to be shown
more clearly then previous work which has included
children [18]. The previous review included 19 unique
RCTSs of which only two are included in this study [31,
37]. The small but significant improvement in for both
asthma control and AQLQ, albeit based on only two
studies, contrasts with evidence from other studies
where no difference was found [18, 40]. In contrast to
other reviews, two studies that analysed asthma symp-
toms showed statistically significant improvements for
intervention patients [18, 40]. Results were mixed for
changes in medication use, improvements in medication
adherence, and health care utilisation. No improvement
in asthma knowledge or reduction in exacerbations was
reported. The small number of studies found is consist-
ent with a recent systematic review of IDIs for asthma
care which showed that only a small proportion of IDIs
were aimed at adults with none including participants
aged over 65 [18].
The review has a number of limitations. Only a small
number of eligible studies were identified. The majority
were of moderate quality, small in size and short in dur-
ation meaning that individual studies were likely to be
under powered for most outcomes. The small number of
studies also meant analysis of the possible effects of spe-
cific intervention components was not possible, limiting
what the study can tell us about the effects of individual
IDIs and how they might differ from each other. The
studies were variable in length, with the longest lasting
one year and the shortest just ten weeks. Short studies
may underestimate the impact of the interventions since
the performance of participants may continue to im-
prove after the end of the intervention [41]. One follow
up study included in this analysis showed that improve-
ments in asthma-related quality of life and asthma con-
trol were sustained in participants for 1.5 years after the
end of the intervention [30].
Included interventions were from a range of countries
(Netherlands, USA, Taiwan and Denmark), suggesting
that IDIs were suitable for use across a range of health
systems. However, none of the trials were undertaken in
low-income countries and there is no evidence on how
intervention effects may differ by socio-economic status
or ethnicity.
Only one study assessed the cost benefits of its impact,
making the cost effectiveness of asthma IDI difficult to
assess [32]. However, this study did suggest that the
intervention could be supplied at similar costs to usual
care, as well as offer additional benefits. Furthermore,
the sustained improvements found in the follow up to
this study suggest that the cost effectiveness may in-
crease over a longer time period [32]. No studies exam-
ined how asthma IDIs may affect mental health.
Conclusion
Digital self-management interventions for adults with
asthma show potential for benefit, with evidence of im-
provements in some outcomes, and no evidence of
harm. However, the evidence base remains weak, and it
is not yet possible to recommend their use in clinical
practice, due to the current lack of large, robust studies
conducted and published.
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